# Quanta Therapeutics

> Quanta Therapeutics is a clinical-stage biopharmaceutical company in South San Francisco building allosteric small-molecule inhibitors for RAS-driven cancers. Using a proprietary Second Harmonic Generation (SHG) optical platform that detects subtle changes in protein conformation, Quanta designs oral drugs aimed at KRAS mutations long considered undruggable - including G12D and G12V - that together drive a large share of pancreatic, colorectal, lung and endometrial cancers. Its lead candidate QTX3034 is in Phase 1 trials, with QTX3544 and a pan-KRAS program close behind.

- **Founded:** 2018
- **Headquarters:** South San Francisco, California, United States
- **Founders:** Perry Nisen (CEO & Board Member (founding Executive Chairman, 2018; CEO since June 2021))
- **Team size:** ~36 employees
- **Products:** QTX3034, QTX3544, QTX6255, RAS-Partner discovery program, SHG drug discovery platform
- **Notable:** Advanced lead candidate QTX3034 into Phase 1 clinical trials for KRAS G12D solid tumors, Secured three FDA IND clearances within roughly one year, Raised over $142 million in total venture financing since 2018

## Products & services

- **QTX3034** — Oral G12D-preferring, multi-KRAS allosteric inhibitor in Phase 1 dose-expansion trials as monotherapy and in combination with cetuximab; enrolling pancreatic, colorectal and endometrial cancer patients with KRAS G12D mutations.
- **QTX3544** — Oral G12V-preferring, dual ON/OFF state multi-KRAS inhibitor; received FDA IND clearance in January 2025 to begin Phase 1.
- **QTX6255** — Pan-KRAS development candidate in IND-enabling activities, designed to address a broad set of KRAS mutations.
- **RAS-Partner discovery program** — Early discovery effort targeting RAS signaling complexes through allosteric modulation of protein-protein interactions.
- **SHG drug discovery platform** — Proprietary high-throughput Second Harmonic Generation optical technology that measures subtle changes in protein conformation to find allosteric modulators of membrane-bound protein complexes.

## Achievements

- Advanced lead candidate QTX3034 into Phase 1 clinical trials for KRAS G12D solid tumors
- Secured three FDA IND clearances within roughly one year
- Raised over $142 million in total venture financing since 2018
- Built a proprietary Second Harmonic Generation platform to drug previously 'undruggable' KRAS conformations
- Presented Phase 1 QTX3034 safety, PK and preliminary efficacy data in October 2025

## Latest updates

- **2025-10** — Presented Phase 1 data for QTX3034 (safety, tolerability, PK and preliminary efficacy) in KRAS G12D solid tumors at a medical conference.
- **2025-07** — Pipeline and corporate update released.
- **2025-01** — FDA cleared the IND for QTX3544, an oral G12V-preferring multi-KRAS inhibitor - Quanta's third IND in about a year.
- **2023-05** — Closed $50.7M Series D financing led by Avidity Partners to advance lead KRAS programs into the clinic.

## Links

- Website: https://quantatx.com
- LinkedIn: https://www.linkedin.com/company/quanta-therapeutics

---

Profile page: https://yespress.io/quanta-therapeutics
Published by YesPress — https://yespress.io
Last updated: 2026-06-13